article thumbnail

DEA Now Allowing Growers To Produce Marijuana For Research

Cannabis Law Report

Drug Enforcement Agency’s approach, the DEA has notified marijuana grower applicants that they soon will be able to register as authorized entities to produce marijuana for research purposes. Prior to this announcement, there was only one DEA-approved supplier of cannabis for research purposes in the entire country.

DEA 105
article thumbnail

DEA removes cannabis drug Epidiolex from controlled substances list

SMPL

Epidiolex, the only plant-derived cannabis drug approved by the U.S. Epidiolex is used to treat rare forms of epilepsy. The DEA’s announcement lowers physician barriers to prescribing Epidiolex because they won’t have to notify the agency when prescribing it. on Tuesday, one day after the U.S. The company’s U.S.

DEA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA. will top $1.9

DEA 51
article thumbnail

HSS Releases Full Recommendation Report for Rescheduling Cannabis: What Will This Mean for Med & Rec Markets?

Veriheal

Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. The recommendation for rescheduling cannabis marked the first time a government agency officially recognized cannabis’ medical benefits.

article thumbnail

Constitutionality of Cannabis: Federal Lawsuit Against DEA, DOJ Proceeds

Marijuana Lawyer Blog

Plaintiffs in the lawsuit include a 12-year-old epilepsy patient, an 8-year-old Leigh’s syndrome patient, an Iraq war veteran and sufferer of post-traumatic stress disorder, a former NFL player who heads a hemp company hawking sports performance products and a non-profit that helps minorities get ahead in the legal cannabis market.

DEA 40
article thumbnail

House Passes Bill to Expand Cannabis and CBD Research

Cannabis Law Report

Among other things, the bill would ease limitations on medical research on cannabis and cannabidiol (CBD). Drug Enforcement Administration (DEA) to register practitioners to conduct cannabis and CBD research and manufacturers to supply cannabis for research purposes. Specifically, the bill would: Direct the U.S.

CBD 52
article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Drug Enforcement Agency (DEA).